Faculty Opinions recommendation of Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial.
Keyword(s):
Phase 1
◽
2020 ◽
Vol 5
(8)
◽
pp. 753-764
◽